<DOC>
	<DOCNO>NCT01648127</DOCNO>
	<brief_summary>The purpose study characterize plasma urinary concentration ceftaroline follow intravenous administration single dose ceftaroline 600 mg healthy subject normal weight , overweight , obese .</brief_summary>
	<brief_title>Pharmacokinetics Ceftaroline Normal Obese Subjects</brief_title>
	<detailed_description>This study plan Phase I , open-label , single period , single-dose pharmacokinetic study conduct 32 healthy adult male female subject . Adult subject recruit assign one four group base body mass index total body weight . Subject receive single dose ceftaroline fosamil 600 mg 1-hour continuous intravenous infusion . Serial blood urine sample collect next 12 hour determine serum urinary pharmacokinetics ceftaroline . Safety evaluation assess throughout study include physical examination , vital sign monitoring , clinical laboratory test ( serum chemistry hematology ) , pregnancy test ( female subject ) , monitor adverse event , record concomitant medication .</detailed_description>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>healthy adult subject nonsmoker within last 1 year body mass index total body weight within specific category history significant hypersensitivity reaction intolerance ceftaroline betalactam agent heparin aspartate alanine aminotransferase &gt; 3 time upper limit normal estimate creatinine clearance &lt; 60 mL/minute serum creatinine &gt; 1.5 mg/dL female subject pregnant breast feed history alcohol substance abuse dependence within last 1 year use prescription nonprescription drug within last 7 14 day participation clinical trial within last 30 day donate blood ( &gt; 500 mL ) within last 56 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Ceftaroline</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Obesity</keyword>
</DOC>